Vivos Therapeutics, Inc. (VVOS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated November 14, 2024, announces the financial results for Vivos Therapeutics, Inc. for the third quarter ended September 30, 2024. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Littleton, Colorado.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the provided text.
Material Changes
The filing does not disclose specific material changes versus the prior comparable period. Investors must refer to the full text of the press release (Exhibit 99.1) for comparative financial analysis.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, management commentary, risk factors, or details on unusual items. The document serves primarily as a notification that the Q3 2024 results have been issued via a press release.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2024 revenue and net loss figures.
- Verify cash position and burn rate details not present in the 8-K cover page.
- Check for any updated clinical trial milestones or regulatory guidance mentioned in the full press release.
- Confirm if the Company provided any forward-looking guidance for the remainder of 2024 or 2025.